News headlines about Strongbridge Biopharma PLC (NASDAQ:SBBP) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Strongbridge Biopharma PLC earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.

Insider Buying and Selling by Quarter for Strongbridge Biopharma PLC (NASDAQ:SBBP)

Several research analysts have commented on the stock. Zacks Investment Research cut shares of Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, May 17th. HC Wainwright restated a “buy” rating on shares of Strongbridge Biopharma PLC in a research report on Wednesday, May 17th.

Strongbridge Biopharma PLC (NASDAQ SBBP) traded up 13.95% during mid-day trading on Tuesday, reaching $4.90. 212,966 shares of the company traded hands. The stock’s 50-day moving average price is $4.46 and its 200-day moving average price is $3.62. Strongbridge Biopharma PLC has a one year low of $2.00 and a one year high of $6.24. The firm’s market cap is $173.14 million.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last announced its quarterly earnings data on Tuesday, May 16th. The biotechnology company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.16. Analysts forecast that Strongbridge Biopharma PLC will post ($2.06) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Strongbridge Biopharma PLC (SBBP) Getting Somewhat Positive Press Coverage, Accern Reports” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at

About Strongbridge Biopharma PLC

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Stock Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related stocks with our FREE daily email newsletter.